

NOV 14 1977



SUBSIDIARY OF MERCK & CO., INC.

CALGON CORPORATION CALGON CENTER BOX 1346 PITTSBURGH, PA. 15230 (412) 923-2345

November 11, 1977

Dr. Joshua Lederberg
Stanford University
J.F. Kennedy Laboratories for Molecular Medicine
Room S-337
Palo Alto, California 94305

Dear Dr. Lederberg:

When I visited with you in October, I promised to send your research proposal on to Merck for their information and review. Dr. Lewis Mandel, Director of Merck's University Relations Department, discussed your research proposal with Dr. Roy Vagelos, President of Merck Sharp & Dohme Research Laboratories.

Dr. Mandel states that in most cases Merck Institute research funding is in amounts of \$15,000 or less. Thus, the amount requested for your first-year research funding is substantially larger than the amount that might be funded by the Merck Institute. As a result, I regret to report that you cannot expect funding support from the Merck Institute.

Further to our recent discussion, we are making progress in our analytical investigation of activated carbon and hope to have our analysis completed within the first quarter of 1978. If and when we are ready to publish our findings, I will see that you receive a pre-publication copy for your review and comment.

Sorry I have been unable to obtain funding for your research program. Nevertheless, I shall look forward to keeping in touch with you in the future.

Sincerely yours,

CALGON CORPORATION

A handwritten signature in cursive script that reads "John H. Mahon".

John H. Mahon, Ph. D.
Vice President
Regulatory and Trade Affairs

JHM:il